Most clinical research on Alzheimer’s disease (AD) has focused on studying individuals at various stages of the disease from preclinical AD to severe dementia as defined by clinical signs and symptoms, cognitive dysfunction, or biomarker evidence of amyloid, tau, and neurodegeneration. This evidence concerns the gene MAPT and dementia.